The presence of food-specific IgA antibodies in the gut does not prevent peanut or egg allergies from developing in children, according to a Northwestern Medicine study published in Science Translational Medicine.
Scientists examined stool samples from more than 500 infants across the country and found that the presence of Immunoglobulin A, the most common antibody found in mucous membranes in the digestive tract, does not prevent peanut or egg allergies from developing later in life.
This discovery calls into question the role of Immunoglobulin A, or IgA, which was previously thought to be a protective factor against the development of food allergies.
Rates of heart failure associated with the growing illicit use of the stimulant drug methamphetamine, or meth for short, are rising worldwide and now affect a wide range of socio-economic and racial groups, finds a review of the available evidence, published online in the journal Heart.
Meth heart failure is also more severe than that experienced by those who don’t use the drug, and warrants increased public awareness and availability of treatment for meth addiction to stem the rising tide of those affected, urge the researchers.
Previously published research shows that use of the drug, also popularly known as “crystal meth,” “ice” and “speed,” is associated with serious health problems, including high blood pressure, heart attack, stroke, and even sudden death. But there are no comprehensive systematic reviews of published research on meth use and heart failure, and this prompted a team of U.S. and Canadian researchers to try to bridge this knowledge gap.
Malaria is found in more than 90 countries around the world, causing 241 million cases and an estimated 627,000 deaths every year. Vaccines are one intervention that could help eliminate this deadly disease, yet a highly effective vaccine remains elusive. Recent technological advances in vaccine development–such as the mRNA vaccines for SARS-CoV2–could lead to a new generation of malaria vaccines.
Now, a research team led by George Washington University has developed two mRNA vaccine candidates that are highly effective in reducing both malaria infection and transmission. The team also found that the two experimental vaccines induced a powerful immune response regardless of whether they were given individually or in combination. The study was published today in npj Vaccines, an open-access scientific journal that is part of the Nature Portfolio.
“Malaria elimination will not happen overnight but such vaccines could potentially banish malaria from many parts of the world,” Nirbhay Kumar, a professor of global health at the George Washington University Milken Institute School of Public Health, said. “The mRNA vaccine technology can really be a game changer. We saw how successful this technology was in terms of fighting COVID and for this study we adapted it and used it to develop tools to combat malaria.”
As Chief Scientist of TRISH, Dr. Fogarty leads an innovative and high-risk research and technology development portfolio to address the most challenging human health and performance risks of space exploration.
At Sophic Synergistics, which is a women-owned and women-led Human Centered Design firm specializing in integrating human factors engineering and human health and performance into a business model, Dr. Fogarty’s Division focuses on developing and expanding the application of medical technologies for use in remote medicine, telemedicine, and home healthcare.
In both roles, Dr. Fogarty’s goal is to increase access to high quality healthcare and empower patients and medical providers by incorporating precision medicine and cutting-edge science and technology with actionable data both in space and on Earth.
Dr. Fogarty has over twenty years of experience in medical physiology and extreme environments and was the NASA Human Research Program Chief Scientist. Her approach prioritizes communication and collaboration with industry academia, government and commercial spaceflight programs, and international partners. She values and seeks collaborations with external institutions and government agencies to assess fundamental and mechanistic discoveries as well as innovative prevention and treatment strategies for application to preserve health and performance.
Dr. Fogarty has a Ph.D. in Medical Physiology from Texas A&M University School of Medicine and a B.S. in Biology from Stockton University. She is currently an Assistant Professor in the Department of Medicine at Baylor College of Medicine, an editor of the Fundamentals of Aerospace Medicine 4th and 5th edition, and associate editor for the journal npj Microgravity.
It is the first ever commercial partnership between Google Health and the medical company iCAD.
Google recently announced that it licensed its AI research prototype to a medical company called iCAD. The AI research model can be used for breast cancer screening. iCAD is a company that creates innovative medical equipment for cancer detection.
ICAD made the announcement about the collaboration yesterday, Nov. 28, on its website.
It is the first time ever that Google Health has licensed this specific artificial intelligence technology in a commercial partnership for breast cancer screening and personalized risk assessment of the disease, to iCAD.
ChooChin/iStock iCAD made the announcement about the collaboration yesterday, Nov. 28, on its website.
Australian researchers have uncovered a new form of antimicrobial resistance (AMR), undetectable using traditional laboratory testing methods, in a discovery set to challenge existing efforts to monitor and tackle one of the world’s greatest health threats.
AMR is expected to claim 10 million lives a year by 2050, with scientists racing to understand and get ahead of the diminishing benefits of antibiotics.
Now, a team led by Dr. Timothy Barnett, Head of the Strep A Pathogenesis and Diagnostics team at the Wesfarmers Centre of Vaccines and Infectious Diseases, based at Telethon Kids Institute in Perth, Western Australia, has unearthed a critical clue to the way some bacteria are managing to dodge antibiotics—a finding expected to be the tip of the iceberg.
I saw a Twitter thread about Bryan Johnson’s ‘Blueprint’, claiming that he’d made himself biologically younger with a highly optimised combination of diet, supplements and exercise. What could that mean? And should we all start chugging 25 pills a day to start on the Blueprint ourselves? Probably not…but the biology behind it is surprisingly interesting.
*Chapters*
00:00 A tweet goes viral. 00:44 Getting ‘biologically younger’ 01:23 NAD levels. 03:09 Maximum heart rate. 04:12 Epigenetic clocks. 07:12 Step 1: the Blueprint diet. 09:23 Step 2: ALL THE SUPPLEMENTS 11:43 Step 3: track progress. 12:40 Conclusion.
*Sources and further reading*
My book, Ageless: The new science of getting older without getting old, goes into far more depth about rapamycin, metformin and epigenetic clocks, and lots more! https://ageless.link/
Colon cancer is the second deadliest cancer in the US. Early detection is important but finding and diagnosing polyps is difficult. 2 AI-powered endoscopes have been developed in Japan to tackle the problem. One can judge a lesion’s malignancy in 0.4 second with almost 100% accuracy. The other indicates lesions during an exam, even indistinct ones, like a car navigation system. We also introduce fermented Japanese foods that are beneficial for gut health and explain how they should be eaten.
While the Apple Watch has evolved from a fashionable phone accessory to a high-tech health monitor—capable of scanning for heart conditions and calling for help after injuries—future generations may tap into a deeper set of features to track the body’s inner workings.
This could include long-rumored blood sugar readings, from the wrist-worn gadget, plus blood pressure measurements, hydration levels and more, following newly divulged arrangements with the sensor maker Rockley Photonics.
As first reported by The Daily Telegraph, Rockley now lists Apple as its biggest customer and contributor of the lion’s share—or potentially nearly all—of its revenues dating back to 2019.
The technology, which was created by Barcelona-based researchers at the Centre for Genomic Regulation (CRG) and the Institute for Research in Biomedicine (IRB Barcelona), combines high-resolution microscopy with sophisticated computer modeling. It is the most comprehensive technique to date for studying the shape of genes.
The new technique allows researchers to create and digitally navigate three-dimensional models of genes, seeing not just their architecture but also information on how they move or how flexible they are. Understanding how genes function might help us better understand how they influence the human body in both health and disease since almost every human disease has some genetic basis.
